Reports
The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.
PRIORITY PRESS - 11th Canadian Immunization Conference
Expanding Protection against Influenza in the Most Vulnerable: Focus on Adjuvanted Influenza Vaccines
Ottawa, Ontario / December 2-4, 2014
Ottawa – The burden of illness associated with influenza infection is considerable, and it is particularly pronounced in the very young and in the elderly. Both groups respond less than optimally to standard influenza vaccines and...
PRIORITY PRESS - 11th Canadian Immunization Conference
Integrating the New Meningococcal B Vaccine into Clinical Practice: Lessons From the Experts
Ottawa, Ontario / December 2-4, 2014
Ottawa – Of the 5 serogroups responsible for invasive meningococcal disease (IMD), serogroup B is by far the most common in Canada today. IMD also disproportionately affects young infants with another peak in incidence in...
PRIORITY PRESS - 56th Annual Meeting of the American Society of Hematology (ASH)
Selecting Second- and Third-Line TKIs in CML: Offering Tolerability in the Context of Indefinite Disease Control
San Francisco, California / December 6-9, 2014
San Francisco - A focus on the relative long-term safety and tolerability of available tyrosine kinase inhibitors (TKIs) for treatment of chronic myeloid leukemia (CML) has been intensified by the evidence that drugs in this class, when...
PRIORITY PRESS - 11th Canadian Immunization Conference
A Primer on HPV Vaccination for Primary Care Practitioners: NACI Recommendations Should Prevail
Ottawa, Ontario / December 2-4, 2014
Ottawa - Primary care providers are required to answer three questions for patients when they come asking about the human papilloma virus (HPV) vaccine: Is it safe? Does it work? And what do you think about it? Providing good,...
PHYSICIAN PERSPECTIVE - Viewpoint based on presentations from the American Heart Association (AHA) 2014 Scientific Sessions
IMPROVE-IT: Reaffirmation of Lipid Hypothesis By Non-Statin Ezetimibe in High-Risk Population
Chicago, Illinois / November 15-19, 2014
Guest Editor: Dr. Paul W. Armstrong, MD, FCAHS, FRSCDistinguished University ProfessorMazankowski Alberta Heart InstituteUniversity of AlbertaEdmonton, Alberta Dr. Armstrong served on the Steering Committee of IMPROVE-IT and was one of...
PRIORITY PRESS - Canadian Cardiovascular Congress (CCC)
The LDL-C Treatment Gap Expected to Be Essentially Closed with New Lipid-Lowering Agents
Vancouver, BC / October 25-28, 2014
Vancouver - Lipid-lowering therapies now in late stages of development are expected to bring the majority of patients to guideline-recommended treatment goals regardless of the reason why they are unable to reach their goal on current...
PRIORITY PRESS - 39th Annual Congress of the European Society for Medical Oncology (ESMO)
Survival Data Justify Early Use of Androgen Pathway Inhibitor in Metastatic Castration Resistant Prostate Cancer
Madrid, Spain / September 26-30, 2014
Madrid - The final overall survival (OS) results of a phase 3 multicentre trial have confirmed the value of first-line androgen inhibition in metastatic castration resistant prostate cancer (mCRPC). In the study, early use of an androgen...
PRIORITY PRESS - 39th Congress of the European Society for Medical Oncology (ESMO)
Objective Response to a TKI in Metastatic Renal Cell Cancer Is Substantially Improved with Individualized Dose Schedules
Madrid, Spain / September 26-30, 2014
Madrid - Optimal response to a tyrosine kinase inhibitor (TKI) employed first line in metastatic renal cell carcinoma (mRCC) appears to be achieved by individualizing the dose and schedule in order to sustain dose intensity, according to...
PRIORITY PRESS - 39th Congress of the European Society for Medical Oncology (ESMO)
Targeted Therapies Moving into First-Line Therapy Underscore Need for Baseline Molecular Testing of Lung Cancers
Madrid, Spain / September 26-30, 2014
Madrid - Guidelines issued by ESMO just prior to the annual Congress call for routine molecular testing at the time of diagnosis in all patients with non-small cell lung cancer (NSCLC). New phase 3 data on ALK-positive (ALK+) NSCLC...